| Name | Title | Contact Details |
|---|
Shockwave Medical is revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque. Inspired by 30-years of safety and efficacy in kidney stone treatment, our Intravascular Lithotrispy family of catheters delivers localized lithotripsy at the site of cardiovascular calcium that enables gentle balloon dilatation of calcified, stenotic arteries. IVL catheters use sonic pressure waves to preferentially impact hard tissue, disrupting calcium, while leaving soft tissue undisturbed. An integrated balloon catheter then dilates the calcified lesion at low-pressure, restoring blood flow. In peripheral vascular clinical study of moderate and severely calcified lesions in 95 patients, IVL demonstrated safety and consistent procedure success with low procedural complications. The technology is inherently familiar, easy to use, operates with just the push of a button, and works with existing cardiovascular treatments. And because it is built on a traditional balloon catheter platform, it integrates seamlessly with clinicians` existing workflow.
Xoran Technologies is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
John R. Dwyer, Jr., JD, serves as the Chief Financial Officer and General Counsel of Telcare, Inc. Mr. Dwyer served as Principal of CodeRyte, Inc. He served as an Executive Vice President of Doctors Health, Inc. and also served as its Chief Financial Officer for 2 years. He served as a Principal of Graham, Hamilton & Dwyer, Inc. (“GHD“). He served as Chief Executive Officer of e-MEDx. He served as Chief Operating Officer of Active Health Management. He served as Chief Executive Officer of Vetcentric, a specialty on-line pharmacy. Mr. Dwyer served at Diametrics, Inc., where he served as President of California-based high technology Company. Mr. Dwyer began his professional career as an Attorney with Arent, Fox, Kintner, Plotkin & Kahn, the fifth largest law firm in Washington, D.C., where he focused on transactions in the health care and telecommunications industries. He serves as the Chairman of Redbricks.com, LLC. He serves on the Boards of a number of private and not-for-profit organizations including Earth Conservation Corp. He serves as a Director of the Trust for America's Health. He serves on the Executive Council of Leaders Engaged against Alzheimer's Disease (LEAD). He serves as a Director of USAgainstAlzheimer's. He served as the Chairman of Telcare, Inc. and serves as its Director. He served as a Director of CodeRyte, Inc. Mr. Dwyer served as a Member of the Obama Administration's HHS transition team and has played an active role in the HHS, FDA, and Commerce transition and staffing plans of the Administration. He co-founded the first political action committee focused on a particular disease, the Alzheimer's Action PAC. Mr. Dwyer is a frequent Speaker on financing and regulatory issues of critical importance to emerging health technology companies. He has spoken on health information issues, business risks associated with the FDA approval process, and patent insurance at a variety of forums including the BIO/CEO and AdvaMed annual conferences. Mr. Dwyer is a graduate of Marquette University and the Cornell University Law School.
At Proof, we believe that knowledge is power—and good health is a necessity. We`re a health technology and diagnostics company that is currently developing a cutting-edge, CRISPR-based platform for point-of-care facilities to test for COVID-19, with ambitions to transform in-home diagnostics across a broad spectrum of health applications in the future. Proof is the brainchild of Professor Feng Zhang, a world-renowned molecular biologist and leader of a research lab at the Broad Institute of MIT and Harvard. In early 2020, Dr. Zhang along with Dr. Jonathan Gootenberg and Dr. Omar Abudayyeh of the McGovern Institute pivoted their focus towards combating the emergent threat of the COVID-19 pandemic. Pioneers of the CRISPR gene-editing technology, the three scientists dropped everything to face the global public health crisis head on. Combining CRISPR and RT-LAMP technologies in a novel approach, our scientific team is developing a simple, streamlined molecular diagnostics platform that can quickly test for the presence of the SARS-CoV-2 virus. Intended for use within clinics, pharmacies, schools, workplaces and eventually homes, our easy-to-use, lab-quality test platform is undergoing rigorous R&D protocols so that we can provide fast, accurate diagnostics that will help communities take control of their health. We want to transform the anxiety of waiting days for COVID-19 test results into the peace of mind of quickly knowing what steps to take next. Our first test system, which we`re designing to detect SARS-CoV-2, will enable us to fulfill our mission of helping restore a degree of normalcy to our world. From there, we aim to transform personalized health, and expand our diagnostic platform to detect other diseases, with the goal of providing actionable health information that will allow people to lead better, healthier lives. If you`re with us, reach out today.
AgaMatrix is revolutionizing health care. We`ve sold over a million devices, two billion sensors, and we are the first FDA cleared medical device/app that works with iOS. AgaMatrix is an inventor and leader in consumer healthcare technology. With fewer than 150 people, almost 50% in R&D, we develop glucose monitoring and management systems for diabetes. Diabetes related care accounts for 20% of all healthcare spending in the US. Our innovative multidisciplinary technology vision includes iPhone, Android, and web applications supported by a cloud-based, Java back end for data management and exchange between patients and their doctors. Our UI/UX won the prestigious red dot design award. Our proprietary tech platform, protected by 126 granted/pending patents, uses DSP algorithms to double accuracy while reducing cost by 50%. AgaMatrix not only developed the first FDA cleared medical device that connects to an iPhone, but has over a dozen other FDA cleared products, and has sold over 2.5M meters and 3B biosensors. Our products are available in 20,000 retail locations and a worldwide in partnership with Sanofi, the world's largest pharmaceutical company. We`ve been featured by the New York Times and Fast Company, and we work with the world`s largest retailers (Walmart, Kroger, Target) and pharmaceutical companies (Sanofi, Perrigo) to change the way diabetes is treated.